UA93538C2 - Aurora kinase modulators and method of use - Google Patents
Aurora kinase modulators and method of useInfo
- Publication number
- UA93538C2 UA93538C2 UAA200810586A UAA200810586A UA93538C2 UA 93538 C2 UA93538 C2 UA 93538C2 UA A200810586 A UAA200810586 A UA A200810586A UA A200810586 A UAA200810586 A UA A200810586A UA 93538 C2 UA93538 C2 UA 93538C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compounds
- kinase
- influencing
- disease states
- modulating
- Prior art date
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to chemical compounds having a general formula (I) wherein A, A, C, C, D, L, L, Z and Rare defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of kinase.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76167506P | 2006-01-23 | 2006-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA93538C2 true UA93538C2 (en) | 2011-02-25 |
Family
ID=40538757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200810586A UA93538C2 (en) | 2006-01-23 | 2007-01-22 | Aurora kinase modulators and method of use |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN101405282B (en) |
| UA (1) | UA93538C2 (en) |
| ZA (1) | ZA200806627B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| HRP20150104T1 (en) * | 2009-09-11 | 2015-03-13 | Amgen, Inc. | N- (4 - ((3- (2-AMINO-4-Pyrimidinyl) -2-pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of cancer resistant ANTIMITOTIC AGENCIES |
| CN103664737A (en) * | 2012-09-25 | 2014-03-26 | 杨子娇 | Compounds for treating narrow chamber angle and application thereof |
| CN112898292A (en) * | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | Novel aurora kinase inhibitor and use thereof |
| CN111039940B (en) * | 2019-12-31 | 2022-10-21 | 北京鑫开元医药科技有限公司 | Aurora A kinase inhibitor, preparation method, pharmaceutical composition and application thereof |
-
2007
- 2007-01-22 CN CN200780009962.1A patent/CN101405282B/en active Active
- 2007-01-22 UA UAA200810586A patent/UA93538C2/en unknown
-
2008
- 2008-07-30 ZA ZA200806627A patent/ZA200806627B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200806627B (en) | 2009-10-28 |
| CN101405282B (en) | 2015-03-25 |
| CN101405282A (en) | 2009-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010517A (en) | Aurora kinase modulators and method of use. | |
| TNSN08310A1 (en) | Aurora kinase modulators and method of use | |
| MX2010010151A (en) | Aurora kinase modulators and method of use. | |
| ATE478861T1 (en) | MULTICYCLIC CONNECTION AND METHOD OF USE | |
| MX2021007157A (en) | Heteroaryl amides useful as kif18a inhibitors. | |
| MXPA06012613A (en) | Protein kinase modulators and method of use. | |
| PH12021551409A1 (en) | Kif18a inhibitors | |
| MX2021007104A (en) | Kif18a inhibitors. | |
| MX2009004060A (en) | Triazolo-pyridazine protein kinase modulators. | |
| TN2009000128A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
| UA95244C2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| EP2331530B8 (en) | Fused multicyclic compounds as protein kinase inhibitors | |
| IN2014KN02886A (en) | ||
| UA104849C2 (en) | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as inhibitors of janus kinases | |
| TW200607513A (en) | Certain chemical entities, compositions, and methods | |
| MY148468A (en) | Compounds and methods for kinase modulation, and indications therefor | |
| MX2009006688A (en) | Compounds and methods for kinase modulation, and indications therefor. | |
| TN2009000142A1 (en) | Bicyclic triazoles as protein kinase modulators | |
| MX2008011258A (en) | Quinazoline derivatives as phosphodiesterase 10 inhibitors. | |
| ATE493418T1 (en) | DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS | |
| ATE532789T1 (en) | DIHYDROTHIENOPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS | |
| TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| MX2007008065A (en) | Compositions and methods for modulating gene expression using self-protected oligonucleotides. | |
| UA100545C2 (en) | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors | |
| WO2010017240A3 (en) | Aurora kinase modulators and methods of use |